272 related articles for article (PubMed ID: 10831638)
1. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux.
Schiffl H; Fischer R; Lang SM; Mangel E
Nephrol Dial Transplant; 2000 Jun; 15(6):840-5. PubMed ID: 10831638
[TBL] [Abstract][Full Text] [Related]
2. Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes.
Campistol JM; Torregrosa JV; Ponz E; Fenollosa B
Contrib Nephrol; 1999; 125():76-85. PubMed ID: 9895432
[No Abstract] [Full Text] [Related]
3. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes.
Randoux C; Gillery P; Georges N; Lavaud S; Chanard J
Kidney Int; 2001 Oct; 60(4):1571-7. PubMed ID: 11576375
[TBL] [Abstract][Full Text] [Related]
4. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis.
van Ypersele de Strihou C; Jadoul M; Malghem J; Maldague B; Jamart J
Kidney Int; 1991 May; 39(5):1012-9. PubMed ID: 2067196
[TBL] [Abstract][Full Text] [Related]
5. Highly permeable and biocompatible membranes and prevalence of dialysis-associated arthropathy.
Kessler M; Netter P; Maheut H; Wolf C; Prenat E; Huu TC; Gaucher A
Lancet; 1991 May; 337(8749):1092-3. PubMed ID: 1673510
[No Abstract] [Full Text] [Related]
6. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations.
Lornoy W; Becaus I; Billiouw JM; Sierens L; Van Malderen P; D'Haenens P
Nephrol Dial Transplant; 2000; 15 Suppl 1():49-54. PubMed ID: 10737167
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.
MacLeod A; Daly C; Khan I; Vale L; Campbell M; Wallace S; Cody J; Donaldson C; Grant A
Cochrane Database Syst Rev; 2001; (3):CD003234. PubMed ID: 11687058
[TBL] [Abstract][Full Text] [Related]
8. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients.
Wanner C; Bahner U; Mattern R; Lang D; Passlick-Deetjen J
Nephrol Dial Transplant; 2004 Oct; 19(10):2570-5. PubMed ID: 15280524
[TBL] [Abstract][Full Text] [Related]
9. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis.
Küchle C; Fricke H; Held E; Schiffl H
Am J Nephrol; 1996; 16(6):484-8. PubMed ID: 8955759
[TBL] [Abstract][Full Text] [Related]
10. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients.
Schiffl H
Hemodial Int; 2014 Jan; 18(1):136-41. PubMed ID: 23718290
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin clearance with high-flux dialysis membranes.
Anandan JV; Touchette MA
Int J Artif Organs; 1998 Mar; 21(3):131-3. PubMed ID: 9622110
[No Abstract] [Full Text] [Related]
12. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
Floege J; Koch KM
Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
[No Abstract] [Full Text] [Related]
13. Long-term clinical experience with PMMA membrane.
Aoike I
Contrib Nephrol; 1999; 125():205-12. PubMed ID: 9895442
[No Abstract] [Full Text] [Related]
14. Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure. A prospective randomized study.
Gastaldello K; Melot C; Kahn RJ; Vanherweghem JL; Vincent JL; Tielemans C
Nephrol Dial Transplant; 2000 Feb; 15(2):224-30. PubMed ID: 10648669
[TBL] [Abstract][Full Text] [Related]
15. Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. International Multicentre Study Group.
Jörres A; Gahl GM; Dobis C; Polenakovic MH; Cakalaroski K; Rutkowski B; Kisielnicka E; Krieter DH; Rumpf KW; Guenther C; Gaus W; Hoegel J
Lancet; 1999 Oct; 354(9187):1337-41. PubMed ID: 10533862
[TBL] [Abstract][Full Text] [Related]
16. Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach.
Cianciolo G; Colí L; La Manna G; Donati G; D'Addio F; Comai G; Ricci D; Dormi A; Wratten M; Feliciangeli G; Stefoni S
Int J Artif Organs; 2007 Oct; 30(10):864-78. PubMed ID: 17992647
[TBL] [Abstract][Full Text] [Related]
17. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress.
Kosch M; Levers A; Fobker M; Barenbrock M; Schaefer RM; Rahn KH; Hausberg M
Nephrol Dial Transplant; 2003 Jul; 18(7):1370-5. PubMed ID: 12808175
[TBL] [Abstract][Full Text] [Related]
18. Improved outcome for haemodialysis patients treated with high-flux membranes.
Woods HF; Nandakumar M
Nephrol Dial Transplant; 2000; 15 Suppl 1():36-42. PubMed ID: 10737165
[TBL] [Abstract][Full Text] [Related]
19. Dialysis-associated amyloidosis.
Sethi D
Ren Fail; 1993; 15(3):349-51. PubMed ID: 8516489
[TBL] [Abstract][Full Text] [Related]
20. Dialysis-related amyloidosis: importance of biocompatibility and age.
Jadoul M
Nephrol Dial Transplant; 1998; 13 Suppl 7():61-4. PubMed ID: 9870440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
